EUVIMEDEUVIMED entdecken
Fallbericht

Dexamethasone intravitreal implant in the treatment of macular edema secondary to necrotizing retinitis

Sergio Copete iD, Jose Gregorio García-García, Enrique Júdez

European Journal of Ophthalmology · 2024

DOI: 10.1177/11206721241275729 ↗

Kurz gefasst

Fallbericht in der Zeitschrift European Journal of Ophthalmology, 2024. Verfasst von Sergio Copete und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Albacete University Hospital, Albacete, Spain. Hauptthemen laut MEDLINE: Dexamethasone, Drug Implants, Glucocorticoids, Intravitreal Injections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To describe our experience with the use of a sustained-release dexamethasone implant in three patients with recalcitrant macular edema that developed after necrotizing retinitis in the context of the previously treated virus. Case description Two immunocompetent patients presented with unilateral acute retinal necrosis (ARN) due to Varicella-Zoster (VZV). The other, an immunocompromised patient, presented with unilateral cytomegalovirus (CMV) necrotizing retinitis. The diagnoses were confirmed by anterior chamber polymerase chain reaction (PCR) and all were treated with oral valganciclovir and intravitreal ganciclovir (2 mg/0.1 ml). Infection was controlled but two of them required pars plana vitrectomy. Between 2 and 4 months after the resolution of signs of infection, resistant macular edema (RME) developed, and an intravitreal dexamethasone device was implanted after anterior chamber PCR had been negative. Functional and anatomical improvement was achieved, with the resolution of the edema accompanied by improvement in visual acuity in all patients. There was no evidence of reactivation at two years. No cataract or ocular hypertension was observed. One patient required two additional dexamethasone implants.

Conclusion

Dexamethasone intravitreal implant could be considered as an option for the treatment of macular edema developed after ARN. Care should be taken to avoid reactivation and patients need to be properly informed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasoneDrug ImplantsGlucocorticoidsIntravitreal InjectionsMacular EdemaRetinal Necrosis Syndrome, AcuteVisual AcuityHumansAntiviral AgentsCytomegalovirus RetinitisEye Infections, ViralHerpes Zoster OphthalmicusHerpesvirus 3, HumanTomography, Optical Coherence

Stichwörter der Autor:innen

UVEITISchoroidal/retinal inflammation < UVEAcomplications of uveitis < UVEITISinfectious endophthalmitis < VITREOUS / ENDOPHTHALMITISretinal herpetic infections < RETINA

Substanzen

Antiviral AgentsDexamethasoneDrug ImplantsGlucocorticoids

Autor:innen und Institutionen

  • Department of Ophthalmology, Albacete University Hospital, Albacete, Spain.
  • Department of Rheumatology, Albacete University Hospital, Albacete, Spain.

ORCID-Profile: Sergio Copete

Zitieren

APA

Copete, S., García-García, J. G., & Júdez, E. (2024). Dexamethasone intravitreal implant in the treatment of macular edema secondary to necrotizing retinitis. European Journal of Ophthalmology. https://doi.org/10.1177/11206721241275729

Vancouver

Copete S, García-García JG, Júdez E. Dexamethasone intravitreal implant in the treatment of macular edema secondary to necrotizing retinitis. European Journal of Ophthalmology. 2024. doi:10.1177/11206721241275729

BibTeX
@article{Copete2024,
  author = {Copete, Sergio and García-García, Jose Gregorio and Júdez, Enrique},
  title = {Dexamethasone intravitreal implant in the treatment of macular edema secondary to necrotizing retinitis},
  journal = {European Journal of Ophthalmology},
  year = {2024},
  doi = {10.1177/11206721241275729}
}
Kostenlos starten →